Table 1 Subject characteristics according to APOE genotype
From: Impact of APOE on amyloid and tau accumulation in argyrophilic grain disease and Alzheimer’s disease
Variable | APOE2 (N = 45) | APOE3 (N = 156) | APOE4 (N = 152) | P-value | |||
|---|---|---|---|---|---|---|---|
N | Median (minimum, maximum) or No. (%) of patients | N | Median (minimum, maximum) or No. (%) of patients | N | Median (minimum, maximum) or No. (%) of patients | ||
Age at death (years) | 45 | 89 (69, 101) | 156 | 89 (59, 100) | 152 | 84 (54, 103) | < 0.001 |
Sex (Male) | 45 | 19 (42.2%) | 156 | 71 (45.5%) | 152 | 84 (55.3%) | 0.14 |
MMSE score | 19 | 25 (17, 29) | 83 | 27 (18, 30) | 31 | 27 (18, 29) | 0.083 |
Braak stage | 45 | 154 | 148 | < 0.001 | |||
0 | 0 (0.0%) | 4 (2.6%) | 2 (1.4%) | ||||
1 | 5 (11.1%) | 17 (11.0%) | 6 (4.1%) | ||||
2 | 13 (28.9%) | 40 (26.0%) | 8 (5.4%) | ||||
3 | 11 (24.4%) | 32 (20.8%) | 12 (8.1%) | ||||
4 | 6 (13.3%) | 34 (22.1%) | 24 (16.2%) | ||||
5 | 4 (8.9%) | 21 (13.6%) | 38 (25.7%) | ||||
6 | 6 (13.3%) | 6 (3.9%) | 58 (39.2%) | ||||
Thal phase | 28 | 105 | 59 | < 0.001 | |||
0 | 9 (32.1%) | 22 (21.0%) | 5 (8.5%) | ||||
1 | 5 (17.9%) | 26 (24.8%) | 3 (5.1%) | ||||
2 | 2 (7.1%) | 12 (11.4%) | 5 (8.5%) | ||||
3 | 6 (21.4%) | 30 (28.6%) | 10 (16.9%) | ||||
4 | 2 (7.1%) | 5 (4.8%) | 6 (10.2%) | ||||
5 | 4 (14.3%) | 10 (9.5%) | 30 (50.8%) | ||||
VaD | 45 | 20 (44.4%) | 156 | 62 (39.7%) | 152 | 41 (27.0%) | 0.019 |
CAA | 45 | 5 (11.1%) | 156 | 6 (3.8%) | 152 | 13 (8.6%) | 0.088 |
TDP-43 | 45 | 2 (4.4%) | 156 | 6 (3.8%) | 152 | 19 (12.5%) | 0.012 |
Synuclein | 45 | 9 (20.0%) | 156 | 25 (16.0%) | 152 | 50 (32.9%) | 0.002 |